Interleukin-5 Antagonist [EPC]

29419 reported adverse events

Drugs of this class: MEPOLIZUMAB RESLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Antagonist [EPC] class:

# Side effect Count
0 ASTHMA 9178
1 DYSPNOEA 7627
2 WHEEZING 5202
3 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 3905
4 COUGH 3749
5 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 3277
6 PNEUMONIA 2864
7 DRUG INEFFECTIVE 2630
8 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 2439
9 PRODUCT DOSE OMISSION ISSUE 2016
See all common reactions for Interleukin-5 Antagonist [EPC]

Drugs of the Interleukin-5 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PLETHYSMOGRAPHY 20 0.9524
1 BRONCHOLITHIASIS 21 0.8077
2 HEART SOUNDS 51 0.6456
3 INSPIRATORY CAPACITY ABNORMAL 18 0.6429
4 SPUTUM CULTURE 18 0.6207
5 TOTAL LUNG CAPACITY INCREASED 97 0.5915
6 AIRWAY REMODELLING 44 0.5176
7 FORCED EXPIRATORY VOLUME 16 0.4706
8 ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME 152 0.4606
9 VITAL CAPACITY DECREASED 171 0.4560
See all enriched reactions for Interleukin-5 Antagonist [EPC]